# US 2025/0032415 A1 · Compositions comprising amino lipid compounds and methods of making and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0032415 A1
- Document ID: US20250032415A1
- Status: Published application
- Kind: A1
- Application number: 18/708,499
- Filed: 2022-11-09
- Published: 2025-01-30
- Earliest claimed: 2021-11-11
- Assignees: Ohio State Innovation Foundation
- Applicants: Ohio State Innovation Foundation
- Inventors: Yizhou DONG; Yonger XUE; Yuebao ZHANG
- Web page: https://patentgrep.com/patent/US20250032415A1

## CPC

- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61P 35/00: Antineoplastic agents
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- C07C 215/14: the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by amino groups
- C07C 219/16: having at least one of the hydroxy groups esterified by an inorganic acid or a derivative thereof
- C07C 229/12: to carbon atoms of acyclic carbon skeletons
- C07C 229/16: to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Disclosed herein are compositions comprising amino lipid compounds and methods of making and use thereof.

## Claims

### Claim 1

A composition comprising a compound defined by Formula I, or a pharmaceutically acceptable salt thereof:
wherein
R10 is substituted or unsubstituted C1-C5 alkyl;
R11 is substituted or unsubstituted C1-C5 alkyl;
R12, R13, and R14 are each independently substituted or unsubstituted C6-C20 alkyl;
with the proviso that when R10 is —C5H10— and R11 is —C3H6—, then R12, R13, and R14 are not all
and
with the proviso that when R10 is —C5H10— and R11 is —C3H6—, then R12, R13, and R14 are not all

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The composition of claim 1, wherein the compound is defined by Formula I-A:
or a pharmaceutically acceptable salt thereof.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The composition of claim 1, wherein the compound is defined by Formula I-B, or a pharmaceutically acceptable salt thereof:
wherein n is an integer from 1 to 5.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The composition of claim 1, wherein R12, R13, and R14 are each independently a substituted or unsubstituted C10-C18 alkyl.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 1)

Tag composition of claim 1, wherein the compound is defined by Formula I-C, or a pharmaceutically acceptable salt thereof:
wherein n is an integer from 1 to 4.

### Claim 19 (depends on 1)

The composition of claim 1, wherein the compound is selected from the group consisting of:
pharmaceutically acceptable salts thereof, and combinations thereof.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23 (depends on 1)

The composition of claim 1, wherein the compound is selected from the group consisting of:
pharmaceutically acceptable salts thereof, and combinations thereof.

### Claim 24

A composition comprising a compound defined by Formula II, or a pharmaceutically acceptable salt thereof:
wherein
R15 is substituted or unsubstituted C1-C5 alkyl;
R16 is substituted or unsubstituted C1-C5 alkyl;
R17, R18, and R19 are each independently substituted or unsubstituted C6-C20 alkyl;
with the proviso that when R15 is —C5H10— and R16 is —C3H6—, then R17, R18, and R19 are not all
and
with the proviso that when R15 is —C5H10— and R16 is —C3H6—, then R17, R18, and R19

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29 (depends on 24)

The composition of claim 24, wherein the compound is defined by Formula II-A:
or a pharmaceutically acceptable salt thereof.

### Claim 30

(canceled)

### Claim 31 (depends on 24)

The composition of claim 24, wherein the compound is defined by Formula II-B, or a pharmaceutically acceptable salt thereof:
wherein m is an integer from 1 to 5.

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35 (depends on 24)

The composition of claim 24, wherein R17, R18, and R19 are each independently a substituted or unsubstituted C10-C18 alkyl.

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41 (depends on 24)

The composition of claim 24, wherein the compound is selected from the group consisting of:
pharmaceutically acceptable salts thereof, and combinations thereof.

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44 (depends on 24)

The composition of claim 24, wherein the compound is selected from the group consisting of:
pharmaceutically acceptable salts thereof, and combinations thereof.

### Claim 45

A composition comprising a compound defined by Formula III, or a pharmaceutically acceptable salt thereof:
wherein
R20 is substituted or unsubstituted C1-C5 alkyl; and
R21 and R22 are each independently substituted or unsubstituted C6-C20 alkyl.

### Claim 46

(canceled)

### Claim 47

(canceled)

### Claim 48

(canceled)

### Claim 49

(canceled)

### Claim 50 (depends on 45)

The composition of claim 45, wherein the compound is defined by Formula III-A:
or a pharmaceutically acceptable salt thereof.

### Claim 51 (depends on 45)

The composition of claim 45, wherein R21 and R22 are each independently a substituted or unsubstituted C10-C18 alkyl.

### Claim 52

(canceled)

### Claim 53

(canceled)

### Claim 54

(canceled)

### Claim 55

(canceled)

### Claim 56

(canceled)

### Claim 57 (depends on 45)

The composition of claim 45, wherein the compound is selected from the group consisting of:
pharmaceutically acceptable salts thereof, and combinations thereof.

### Claim 58 (depends on 45)

The composition of claim 45, wherein the compound is selected from the group consisting of:
pharmaceutically acceptable salts thereof, and combinations thereof.

### Claim 59

(canceled)

### Claim 60

(canceled)

### Claim 61 (depends on 1)

A lipid particle comprising the composition of claim 1.

### Claim at position 62

62-76. (canceled)
